Home
-
CDMOs/CMOs & Tariffs: The Next Move
The White House extended the deadline to impose reciprocal tariffs on most countries until August 1st. What is the impact on manufacturing & supply lines, and what may be next?
-
Mid-Year Review: New Drug Approvals—Up or Down?
With budgetary and staffing cuts at FDA, have approvals of new drugs slowed? DCAT Value Chain Insights looks at the numbers and key trends in new drug approvals thus far in 2025.
-
Cell and Gene Therapies: How is the Market Faring?
Cell and gene therapies are a niche segment in the global bio/pharmaceutical market. What are leading products, and what are key developments thus far in 2025?
DCAT MEMBER COMPANY COMMUNITY
-
DCAT Awards Grants To Student Scientists at the 2025 Regeneron International Science & Engineering Fair
The Drug, Chemical & Associated Technologies Association (DCAT) has awarded $30,000 in grants to student scientists of four projects who participated in the Regeneron International Science & Engineering Fair (Regeneron…
-
ICYMI: DCAT Production to Prescription Podcast: “Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?”
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, a key…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
New Podcast Episode! Biomanufacturing: How are Industry Capacity & Supply Chains Trending?
What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies)? Is there too much capacity or is the market tight? The latest episode of…
